Khurram Jamil's most recent trade in Galectin Therapeutics Inc was a trade of 60,000 Common Stock done . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 60,000 | 60,000 (0%) | 0% | 0 | Common Stock | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 60,000 | 0 | - | - | Restricted Stock Unit | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.90 per share. | 02 Jan 2026 | 25,499 | 21,446 (0%) | 0% | 3.9 | 99,408 | Common stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.65 per share. | 02 Jan 2026 | 21,446 | 0 (0%) | 0% | 3.6 | 78,205 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.20 per share. | 02 Jan 2026 | 13,055 | 46,945 (0%) | 0% | 4.2 | 54,789 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 8,125 | 40,625 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.07 per share. | 31 Dec 2025 | 8,125 | 0 (0%) | 0% | 4.1 | 33,089 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 31 Dec 2025 | 8,125 | 8,125 (0%) | 0% | 1.2 | 9,994 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. | 17 Dec 2025 | 8,500 | 8,500 (0%) | 0% | 2.5 | 21,250 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.04 per share. | 17 Dec 2025 | 8,500 | 0 (0%) | 0% | 7.0 | 59,840 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2025 | 8,500 | 50,000 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.04 per share. | 17 Dec 2025 | 6,463 | 0 (0%) | 0% | 7.0 | 45,500 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.20 per share. | 17 Dec 2025 | 6,463 | 6,463 (0%) | 0% | 2.2 | 14,219 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2025 | 6,463 | 102,037 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.04 per share. | 17 Dec 2025 | 4,479 | 0 (0%) | 0% | 7.0 | 31,532 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 41,500 | 58,500 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.47 per share. | 13 Nov 2025 | 41,500 | 4,479 (0%) | 0% | 5.5 | 227,005 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 41,500 | 108,500 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. | 13 Nov 2025 | 41,500 | 45,979 (0%) | 0% | 2.5 | 103,750 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.47 per share. | 13 Nov 2025 | 41,500 | 4,479 (0%) | 0% | 5.5 | 227,005 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.20 per share. | 13 Nov 2025 | 41,500 | 45,979 (0%) | 0% | 2.2 | 91,300 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.47 per share. | 13 Nov 2025 | 21,867 | 4,479 (0%) | 0% | 5.5 | 119,612 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.47 per share. | 13 Nov 2025 | 16,250 | 4,479 (0%) | 0% | 5.5 | 88,888 | Common stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 13 Nov 2025 | 16,250 | 20,729 (0%) | 0% | 1.2 | 19,988 | Common stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 16,250 | 48,750 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Restricted Stock Unit | |
| Galectin Therapeutics Inc | Jamil Khurram | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 40,000 | 40,000 (0%) | 0% | 0 | Common Stock | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 40,000 | 0 | - | - | Restricted Stock Units | |
| Galectin Therapeutics Inc | Jamil Khurram | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 23 Dec 2024 | 13,654 | 26,346 (0%) | 0% | 0.9 | 12,044 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 10,000 | 10,000 | - | - | Restricted Stock Unit |